SCHEMBL533714

SCHEMBL533714

CC(C)(C)OC(=O)N(c1cccc(C(Cc2ccc(-c3ccc(F)cc3)cc2)NS(=O)(=O)c2cccnc2)n1)C(C(=O)O)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER2 P43116 7/20 0.40
ADAMTS4 O75173 3/20 0.36
MMP13 P45452 2/20 0.36
SCN9A Q15858 1/20 0.35
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGAV P06756 1/20 0.34
GPR132 Q9UNW8 1/20 0.33
USP30 Q70CQ3 2/20 0.33
FPR1 P21462 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP7 P09237 1/20 0.33
MMP9 P14780 1/20 0.33
PTPRB P23467 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL534320 0.95 PTGER2 (0.38) PTGER2ADAMTS4SLC1A3SLC1A2SLC1A1
SCHEMBL534170 0.93 PTGER2 (0.40) PTGER2ADAMTS4SLC1A3SLC1A2SLC1A1
SCHEMBL534195 0.92 PTGER2 (0.41) PTGER2ADAMTS4SLC1A3SLC1A2SLC1A1
SCHEMBL533795 0.91 SLC1A3 (0.35) PTGER2ADAMTS4MMP13SLC1A3SLC1A2
SCHEMBL533698 0.90 PTGER2 (0.42) PTGER2ADAMTS4MMP13SCN9ASLC1A3
SCHEMBL10322183 0.90 PTPRB (0.35) PTGER2ADAMTS4SLC1A3SLC1A2SLC1A1
SCHEMBL10323317 0.89 SLC1A3 (0.34) PTGER2ADAMTS4SLC1A3SLC1A2SLC1A1
SCHEMBL17472618 0.89 PTGER2 (0.47) PTGER2ADAMTS4MMP13ITGB3ITGAV
SCHEMBL533289 0.88 PTGER2 (0.43) PTGER2SLC1A3SLC1A2SLC1A1
SCHEMBL13571751 0.88 PTGER2 (0.42) PTGER2ADAMTS4SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP disclosed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US disclosed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 PTGER2 24/4885ADAMTS4 3278/4885MMP13 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.